Biomea Fusion, Inc.

Stage 3 · Topping · week 1

As of Oct 22, 2026, Biomea Fusion is in Stage 3, the topping phase, now in its first week (since Oct 20, 2026). It closed at $0.59, 73.5% below its 52-week high and below its 200-day average, which is falling.

$0.59

-15.22% today

$42.3M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is BMEA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 14w

S1 14w

S4 20w

S4 30w

S4 14w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 3w → S4 14w → S1 14w → S2 2w → S3 2w → S4 20w → S1 11w → S4 30w → S1 3w → S4 3w → S1 2w → S4 5w → S1 5w → S4 14w → S1 7w → S4 2w → S1 4w → S2 6w → S3 2w → S4 9w → S1 1w → S2 7w → S3 1w current

Total tracked: 166 weeks across 23 stage runs.

BMEA among Biotechnology414th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…414	BMEABiomea Fusion, Inc.	Stage 3 · wk 1	17	−59.4%

vs 52W High

-73.5%

$0.59 lo$2.21 hi

73.5% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 1

1w13w26w

Week 1, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-58.1%

200 DMA: $1.40 · sloping down

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.79x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-59.4%

-53.2%

-68.7%

YTD

-56.3%

-63.2%

Scan Membership

Breakout Watch

Latest: 2024-03-27

3 appearances in last 60 days. First seen: 2022-07-18.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 1 · Vol 0.79x

2026-10-21S3

Wk 1 · Vol 1.25x

2026-10-20S32→3

Wk 1 · Vol 1.50x

2026-10-19S2

Wk 7 · Vol 0.67x

2026-10-16S2

Wk 7 · Vol 1.66x

2026-10-15S2

Wk 7 · Vol 1.41x

2026-10-14S2

Wk 6 · Vol 5.85x

2026-10-13S2

Wk 6 · Vol 4.49x

2026-10-12S2

Wk 6 · Vol 3.06x

2026-10-09S2

Wk 6 · Vol 0.67x

2026-10-08S2

Wk 6 · Vol 1.00x

2026-10-07S2

Wk 5 · Vol 0.49x

Moving averages & range

50 DMA

$1.44

200 DMA

$1.40

52W High

$2.21

52W Low

$0.59

5D Low

$0.59

Resistance levels (recent highs)

20d High

$1.42

60d High

$2.03

120d High

$2.03

250d High

$2.21

Next resistance

+142.7%

to 20d High

ROE

-164.1%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 3.5

Biomea Fusion: quick answers

What stage is Biomea Fusion in?

As of Oct 22, 2026, Biomea Fusion (BMEA) is in Stage 3, the topping phase. It entered Stage 3 on Oct 20, 2026 and is in its first week there. What the four stages mean

Is Biomea Fusion in an uptrend?

Its uptrend has stalled. Biomea Fusion is in Stage 3, the topping phase that follows an advance. It trades 58.1% below its 200-day average, which is falling.

How far is Biomea Fusion from its 52-week high?

Biomea Fusion closed at $0.59 on Oct 22, 2026, 73.5% below its 52-week high of $2.21. Its 52-week low is $0.59.

How has Biomea Fusion performed over the past year?

As of Oct 22, 2026, Biomea Fusion is down 63.2% over the past year and down 56.3% so far in 2026.

Which sector and industry is Biomea Fusion in?

Biomea Fusion is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.